Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.

Huang, Chu-Ying

Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study. [electronic resource] - Oncotarget Oct 2016 - 66480-66490 p. digital

Publication Type: Journal Article

1949-2553

10.18632/oncotarget.5515 doi


Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bone Neoplasms--drug therapy
Carcinoma, Non-Small-Cell Lung--drug therapy
Crown Ethers--administration & dosage
Diphosphonates--administration & dosage
Disease-Free Survival
ErbB Receptors--antagonists & inhibitors
Erlotinib Hydrochloride--administration & dosage
Female
Gefitinib
Humans
Imidazoles--administration & dosage
Kaplan-Meier Estimate
Lung Neoplasms--drug therapy
Male
Middle Aged
Mutation
Pamidronate
Protein Kinase Inhibitors--administration & dosage
Quinazolines--administration & dosage
Retrospective Studies
Treatment Outcome
Zoledronic Acid